DS 8273

Drug Profile

DS 8273

Alternative Names: Anti-DR5 monoclonal antibody - Daiichi Sankyo; DS-8273a; DS8273

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Inc
  • Developer Bristol-Myers Squibb; Daiichi Sankyo Inc; New York University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Lymphoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 29 Sep 2017 Bristol-Myers Squibb terminates a phase I trial due to business decision in Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Combination therapy) in USA (IV) (NCT02991196)
  • 01 Apr 2017 Interim safety and efficacy data from a phase I trial in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Dec 2016 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Combination therapy) in USA (IV) (NCT02991196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top